Fizazi, et al. ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). ASCO-GU 2019, abstract 140.
177Lu-Dotataat plus octreotide bij neuro-endocriene tumoren: NETTER-2
sep 2024 | Maag-darm-leveroncologie